Targeted Talks
S8 Ep9: Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
7:00
On this episode of Targeted Talks, Lyudmila Bazhenova, MD, discusses the FDA’s expanded label approval of taletrectinib (Ibtrozi) for ROS1-positive non–small cell lung cancer (NSCLC). She explains that the approval is based on data already presented at the 2026 AACR Annual Meeting, which showed efficacy in both TKI-naive and TKI-pretreated patients with longer follow-up. In TKI-naive patients,…